title: The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review.
abstract: Tacrolimus ointment and pimecrolimus cream are approved in the United States for treatment of atopic dermatitis. Tacrolimus and pimecrolimus are both calcineurin inhibitors and function as immunosuppressants. Their mechanisms have been discussed elsewhere. This article will discuss their utility in treating psoriasis.
authors.affiliation: Department of Dermatology, St Lukes Roosevelt Hospital, New York NY, USA. Scheinfeld@earthlink.net
authors.forename: Noah
authors.initials: N
authors.lastname: Scheinfeld
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D065095:Calcineurin Inhibitors; D002626:Chemistry, Pharmaceutical; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D005148:Facial Dermatoses / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008081:Liposomes; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D009779:Occlusive Dressings; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012869:Skin Absorption; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D008081:Liposomes; D009824:Ointments; C117268:pimecrolimus; D016559:Tacrolimus